C1QA Gene — Complement Component 1q A Chain

c1q
Symbol	C1Q
Full Name	c1q
Type	Gene
NCBI	Search NCBI
Associated Diseases	AD, ALI, ALS, ALZHEIMER, ALZHEIMER'S DISEASE
KG Connections	1048 edges

Introduction

C1QA encodes the A-chain of complement component C1q, a core initiator of the classical complement pathway and a major regulator of immune signaling in the central nervous system (CNS). In the healthy brain, C1q participates in developmental synaptic refinement and immune surveillance. In aging and neurodegeneration, C1q expression rises strongly in vulnerable regions and is linked to maladaptive synapse elimination, microglial activation, and circuit dysfunction. ^{1The classical complement cascade mediates CNS synapse elimination2007 · Cell · PMID 18083105Open reference 2Complement and microglia mediate early synapse loss in Alzheimer mouse models2016 · Science · PMID 27033548Open reference 3Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer's disease2018 · Neuron · PMID 30415998Open reference}

C1q is produced by CNS myeloid-lineage cells (especially Microglia) and, in disease contexts, can localize to synapses, dystrophic neurites, extracellular protein aggregates, and vascular interfaces. These features make C1QA a high-value node connecting innate immunity, synaptic biology, and disease progression in Alzheimer’s Disease, Parkinson’s Disease, and related disorders. ^{2Complement and microglia mediate early synapse loss in Alzheimer mouse models2016 · Science · PMID 27033548Open reference 4Neurotoxic reactive astrocytes are induced by activated microglia2017 · Nature · PMID 28099414Open reference 5Possible involvement of complement factor C1q in the clearance of extracellular neuromelanin from the substantia nigra in Parkinson disease2011 · Journal of Neuropathology and Experimental Neurology · PMID 21343881Open reference}

Overview

C1QA encodes the A-chain of complement component C1q, a pattern-recognition molecule that serves as the initiating complex of the classical complement cascade. The C1q complex consists of six heterotrimeric subunits (three A, three B, three C chains) that assemble into a characteristic “bouquet of tulips” structure, with globular heads that recognize diverse molecular targets and collagen-like tails that engage downstream C1r and C1s serine proteases. ^{1The classical complement cascade mediates CNS synapse elimination2007 · Cell · PMID 18083105Open reference}

In the nervous system, C1q performs dual roles: during development, it participates in activity-dependent synaptic refinement through complement-mediated microglial phagocytosis; in the adult and aging brain, it maintains immune surveillance functions. However, dysregulated C1q expression in neurodegenerative conditions triggers pathological synapse loss, neuroinflammation, and exacerbates protein pathology propagation. ^{6C1q interacts with TLR4 to induce neuroinflammation in Parkinson's disease2019 · Journal of Neuroinflammation · PMID 31733751Open reference 7Microglial complement receptor 3 regulates brain Aβ and tau pathology2017 · Journal of Experimental Medicine · PMID 29282216Open reference}

Gene And Protein Context

• Symbol: C1QA

• Full name: Complement C1q A chain

• Chromosomal locus: 1p36.12

• NCBI Gene: 712

• Ensembl: ENSG00000173372

• UniProt (protein subunit): P02745

• Protein molecular weight: ~26 kDa (A chain), assembled complex ~410 kDa

• Expression: Primarily expressed in myeloid cells (monocytes, macrophages, microglia); astrocytic expression detected in disease states

The mature C1q complex is assembled from C1QA, C1QB, and C1QC subunits into a bouquet-like pattern-recognition molecule. Each chain contributes to collagen-like domains and globular heads that bind immune targets and altered host surfaces. In brain tissue, this structure allows C1q to bind synaptic elements and trigger downstream complement activity through C3 Protein and complement receptors. ^{1The classical complement cascade mediates CNS synapse elimination2007 · Cell · PMID 18083105Open reference 2Complement and microglia mediate early synapse loss in Alzheimer mouse models2016 · Science · PMID 27033548Open reference}0

Molecular Mechanisms In The Nervous System

Complement Cascade Initiation

C1q functions as the recognition component of the C1 complex (C1qr2s2). Upon binding to pathogen-associated molecular patterns (PAMPs), damage-associated molecular patterns (DAMPs), or altered self-surfaces including aggregated proteins and synaptic membranes, C1q undergoes conformational changes that activate the associated C1r and C1s serine proteases. This triggers the classical complement cascade, leading to C4b/C2b cleavage and formation of the C3 convertase (C4b2a), which then generates downstream effectors including C3a and C3b opsonins. ^{2Complement and microglia mediate early synapse loss in Alzheimer mouse models2016 · Science · PMID 27033548Open reference}1

In the CNS, C1q can be activated by multiple triggers relevant to neurodegeneration: amyloid-beta plaques, hyperphosphorylated tau aggregates, alpha-synuclein fibrils, and complement-opsonized synapses. The resulting complement activation creates a self-amplifying loop where early synaptic tagging by C1q leads to C3-mediated microglial phagocytosis. ^{2Complement and microglia mediate early synapse loss in Alzheimer mouse models2016 · Science · PMID 27033548Open reference}2

Synaptic Pruning: Development vs. Disease

During postnatal brain development, C1q marks surplus synapses for elimination in an activity-dependent manner. Synaptic activity modulates the complement tagging system: more active synapses are protected through unknown mechanisms while less active synapses become tagged with C1q and subsequently eliminated by microglia via complement receptor 3 (CR3/CD11b/CD18). This developmental pruning refines neural circuits and establishes appropriate connectivity. ^{2Complement and microglia mediate early synapse loss in Alzheimer mouse models2016 · Science · PMID 27033548Open reference}3

In neurodegenerative disease, this developmental program appears to be reactivated pathologically. Multiple mechanisms contribute to inappropriate C1q-mediated synapse loss:

1. Age-related C1q increase: C1q protein levels in brain tissue increase dramatically with normal aging, particularly in hippocampus and cortex. This age-related “priming” lowers the threshold for pathological synapse elimination. ^{2Complement and microglia mediate early synapse loss in Alzheimer mouse models2016 · Science · PMID 27033548Open reference}4

2. Disease-specific triggers: Amyloid-beta, tau, and alpha-synuclein aggregates can directly or indirectly activate the classical complement pathway, leading to excessive C1q deposition on synapses. ^{2Complement and microglia mediate early synapse loss in Alzheimer mouse models2016 · Science · PMID 27033548Open reference}5

3. Microglial activation: Primed or disease-associated microglia exhibit enhanced complement production and respond more aggressively to C1q-opsonized targets. ^{2Complement and microglia mediate early synapse loss in Alzheimer mouse models2016 · Science · PMID 27033548Open reference}6

4. Astrocytic C1q: Emerging evidence shows astrocytes can produce C1q in response to inflammatory signals, potentially contributing to synaptic loss through non-microglial mechanisms. ^{2Complement and microglia mediate early synapse loss in Alzheimer mouse models2016 · Science · PMID 27033548Open reference}7

Interaction With Pattern Recognition Receptors

C1q interacts with multiple pattern recognition receptors beyond the classical complement pathway. Notably, C1q can engage Toll-like receptor 4 (TLR4) on microglia, triggering NF-κB-dependent inflammatory cytokine production. This TLR4-C1q interaction provides a molecular link between complement activation and the broader neuroinflammatory response in Parkinson’s disease and potentially other neurodegenerative conditions. ^{2Complement and microglia mediate early synapse loss in Alzheimer mouse models2016 · Science · PMID 27033548Open reference}8

Physiologic Function In The Nervous System

Complement initiation and immune surveillance

C1q recognizes molecular patterns and initiates classical complement signaling. In CNS tissue, this can support debris clearance and immune homeostasis under tightly constrained conditions. The complement system provides a first line of defense against pathogens and facilitates clearance of apoptotic cells and protein aggregates. ^{2Complement and microglia mediate early synapse loss in Alzheimer mouse models2016 · Science · PMID 27033548Open reference}9 ^{3Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer's disease2018 · Neuron · PMID 30415998Open reference}0

Synapse refinement

During development, C1q tags subsets of synapses for microglial pruning. This process helps optimize connectivity but becomes pathologic when re-engaged in aged or diseased brain circuits. The balance between protective and pathological C1q function depends on context, with developmental pruning being highly regulated whereas disease-associated pruning becomes dysregulated. ^{3Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer's disease2018 · Neuron · PMID 30415998Open reference}1 ^{3Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer's disease2018 · Neuron · PMID 30415998Open reference}2

Glial crosstalk

C1q is also part of a microglia-astrocyte signaling axis: activated microglia can release C1q alongside cytokine mediators that drive reactive astrocyte programs. This links complement activity to broader neuroinflammatory states and secondary neuronal stress. The microglial-astrocyte crosstalk mediated by C1q and related complement components contributes to the emergence of neurotoxic reactive astrocytes. ^{3Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer's disease2018 · Neuron · PMID 30415998Open reference}3

Vascular interface functions

C1q localizes to cerebral vasculature and may participate in blood-brain barrier maintenance and vascular clearance pathways. In disease states, C1q deposition at the neurovascular unit could contribute to vascular dysfunction and impaired clearance of toxic proteins. ^{3Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer's disease2018 · Neuron · PMID 30415998Open reference}4

Role In Neurodegeneration

Alzheimer’s disease

Multiple lines of evidence connect C1q to early synaptic injury in AD models. Complement-dependent synapse loss can occur before large-scale neuronal death and correlates with cognitive decline. C1q engagement with Microglial Synaptic Pruning Dysregulation in Neurodegeneration and Complement-Mediated Synapse Loss is now a central mechanistic framework. ^{3Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer's disease2018 · Neuron · PMID 30415998Open reference}5 ^{3Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer's disease2018 · Neuron · PMID 30415998Open reference}6 ^{3Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer's disease2018 · Neuron · PMID 30415998Open reference}7

The temporal sequence of events in AD models suggests that soluble oligomeric amyloid-beta (the most synaptotoxic species) induces C1q expression and synapse tagging before plaques become extensive. This C1q-dependent mechanism may explain why synapse loss precedes neuronal loss in AD and why cognitive deficits appear early in disease progression. ^{3Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer's disease2018 · Neuron · PMID 30415998Open reference}8 ^{3Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer's disease2018 · Neuron · PMID 30415998Open reference}9

Importantly, C1q appears to synergize with other AD-related mechanisms. Tau pathology propagates via complement-dependent mechanisms, and C1q antibodies can rescue tau-induced synapse loss in model systems. This suggests a potential therapeutic approach targeting complement to preserve synapses across multiple pathological substrates. ^{2Complement and microglia mediate early synapse loss in Alzheimer mouse models2016 · Science · PMID 27033548Open reference}0

Tauopathies and other dementias

Human tauopathy datasets report complement dysregulation with C1q/C3 pathway involvement, reinforcing the idea that complement activation is not restricted to amyloid-dominant settings. Studies in Alzheimer’s disease, progressive supranuclear palsy, corticobasal degeneration, and primary tauopathies all show evidence of complement activation that correlates with disease severity. ^{2Complement and microglia mediate early synapse loss in Alzheimer mouse models2016 · Science · PMID 27033548Open reference}1

The relationship between tau pathology and complement appears bidirectional: tau pathology activates complement, and complement activation may in turn accelerate tau propagation through microglial-mediated mechanisms. This creates a feed-forward loop that could explain the stereotypical progression of tau pathology in the aging brain. ^{2Complement and microglia mediate early synapse loss in Alzheimer mouse models2016 · Science · PMID 27033548Open reference}2

Parkinsonian syndromes

Pathologic studies in PD substantia nigra describe C1q involvement in neuromelanin-associated immune responses. Although disease effects likely vary by region and stage, complement signaling remains a plausible contributor to chronic microglial activation in nigrostriatal degeneration. The interaction between neuromelanin release from dying neurons and complement activation provides a mechanism for chronic neuroinflammation in PD. ^{2Complement and microglia mediate early synapse loss in Alzheimer mouse models2016 · Science · PMID 27033548Open reference}3

Additionally, C1q interactions with TLR4 on microglia induce pro-inflammatory responses that could contribute to dopaminergic neuron vulnerability. The convergence of complement and pattern recognition receptor signaling provides a molecular framework for understanding how protein aggregates trigger neuroinflammation across synucleinopathies. ^{2Complement and microglia mediate early synapse loss in Alzheimer mouse models2016 · Science · PMID 27033548Open reference}4

Amyotrophic lateral sclerosis (ALS)

Complement activation, including C1q deposition, has been documented in ALS models and human tissue. Given the prominence of synaptic dysfunction in ALS and the role of complement in synapse elimination, C1q-mediated mechanisms may contribute to early synaptic pathology in motor neuron disease. However, this area remains less characterized than AD and PD.

Disease Associations And Translational Relevance

AD risk biology

C1q-dependent synaptic pruning is increasingly viewed as an upstream driver of network failure rather than only a late epiphenomenon. The demonstration that C1q blockade preserves synapses and improves cognitive outcomes in multiple AD models has solidified this perspective. Therapeutic targeting of C1q represents a strategy to intervene in disease progression before irreversible neuronal loss occurs. ^{2Complement and microglia mediate early synapse loss in Alzheimer mouse models2016 · Science · PMID 27033548Open reference}5 ^{2Complement and microglia mediate early synapse loss in Alzheimer mouse models2016 · Science · PMID 27033548Open reference}6

Aging vulnerability

Marked age-related C1q accumulation may lower the threshold for complement overactivation after proteotoxic or vascular stress. This “inflammaging” effect on complement systems could explain why neurodegenerative diseases predominantly affect older adults. Interventions that normalize C1q levels or function might therefore have particular utility in the aging population. ^{2Complement and microglia mediate early synapse loss in Alzheimer mouse models2016 · Science · PMID 27033548Open reference}7

Therapeutic strategy

Targeting early complement nodes (C1q/C3 axis) is under active translational investigation to preserve synapses while avoiding broad immunosuppression. Multiple approaches are being explored:

1. Anti-C1q antibodies: Monoclonal antibodies that block C1q function have shown efficacy in preclinical models. These agents could prevent pathological synapse tagging while sparing beneficial developmental pruning. ^{2Complement and microglia mediate early synapse loss in Alzheimer mouse models2016 · Science · PMID 27033548Open reference}8 ^{2Complement and microglia mediate early synapse loss in Alzheimer mouse models2016 · Science · PMID 27033548Open reference}9

2. Small molecule inhibitors: Small molecules that block C1q-target interactions or prevent C1 complex assembly represent an alternative approach with potentially different pharmacokinetic properties. ^{4Neurotoxic reactive astrocytes are induced by activated microglia2017 · Nature · PMID 28099414Open reference}0

3. CR3/CD11b modulation: Since microglia mediate synapse elimination through CR3, modulating this receptor provides another potential intervention point. ^{4Neurotoxic reactive astrocytes are induced by activated microglia2017 · Nature · PMID 28099414Open reference}1

4. Astrocyte-targeted approaches: Given the emerging role of astrocytic C1q production, targeting astrocyte-specific complement expression could provide more targeted effects. ^{4Neurotoxic reactive astrocytes are induced by activated microglia2017 · Nature · PMID 28099414Open reference}2

Non-human primate studies have demonstrated that C1q inhibition can prevent age-related synaptic loss, supporting the translational relevance of this approach. ^{4Neurotoxic reactive astrocytes are induced by activated microglia2017 · Nature · PMID 28099414Open reference}3

Biomarker linkage

C1q biology intersects with inflammatory and glial biomarker programs (for example sTREM2 (Soluble TREM2) - Microglial Biomarker). Measurement of C1q levels in cerebrospinal fluid and plasma could provide insights into complement activation status in patients, potentially serving as a biomarker for disease stage or treatment response. Additionally, genetic variants in complement genes may influence AD risk, though the relationship remains complex. ^{4Neurotoxic reactive astrocytes are induced by activated microglia2017 · Nature · PMID 28099414Open reference}4

Experimental Models And Methods

Common approaches used to study C1QA in neurodegeneration include:

1. Genetic perturbation: C1qa knockout or complement-pathway manipulation in mouse models for causal testing of synapse loss and behavioral outcomes. Knockout mice are protected from synapse loss in multiple models, providing strong evidence for C1q’s pathological role. ^{4Neurotoxic reactive astrocytes are induced by activated microglia2017 · Nature · PMID 28099414Open reference}5 ^{4Neurotoxic reactive astrocytes are induced by activated microglia2017 · Nature · PMID 28099414Open reference}6

2. Histology and spatial mapping: region-resolved quantification of C1q deposition on synaptic markers, neurites, and glial compartments. Techniques include confocal microscopy, array tomography, and spatial transcriptomics. ^{4Neurotoxic reactive astrocytes are induced by activated microglia2017 · Nature · PMID 28099414Open reference}7 ^{4Neurotoxic reactive astrocytes are induced by activated microglia2017 · Nature · PMID 28099414Open reference}8

3. Single-cell and transcriptomic analyses: mapping C1QA-enriched glial states and coupling them to progression-stage phenotypes. Single-cell RNA sequencing has identified C1q-expressing microglial clusters associated with neurodegeneration. ^{4Neurotoxic reactive astrocytes are induced by activated microglia2017 · Nature · PMID 28099414Open reference}9

4. Interventional pharmacology: pathway-level inhibition of complement signaling in preclinical paradigms to test rescue of synaptic and cognitive endpoints. Antibody blockade, genetic knockouts, and small molecule inhibitors have all been tested. ^{5Possible involvement of complement factor C1q in the clearance of extracellular neuromelanin from the substantia nigra in Parkinson disease2011 · Journal of Neuropathology and Experimental Neurology · PMID 21343881Open reference}0

5. Human tissue studies: Postmortem brain tissue analysis from AD, PD, and other neurodegenerative disease patients to validate findings from model systems. Human studies confirm increased C1q expression and deposition in disease states. ^{5Possible involvement of complement factor C1q in the clearance of extracellular neuromelanin from the substantia nigra in Parkinson disease2011 · Journal of Neuropathology and Experimental Neurology · PMID 21343881Open reference}1

6. iPSC models: Human-induced pluripotent stem cell-derived neurons and microglia allow study of C1q effects in human cells, potentially identifying species-specific mechanisms. ^{5Possible involvement of complement factor C1q in the clearance of extracellular neuromelanin from the substantia nigra in Parkinson disease2011 · Journal of Neuropathology and Experimental Neurology · PMID 21343881Open reference}2

Clinical Trials And Therapeutic Development

While no C1q-targeted therapies have reached late-stage clinical trials for neurodegenerative diseases as of 2024, several programs are in development:

• Anti-C1q antibodies have completed preclinical development and may enter clinical trials for AD

• Complement inhibitors from other indications (e.g., eculizumab for atypical hemolytic uremic syndrome) have been repurposed in pilot studies for neurological conditions

• Gene therapy approaches to modulate complement expression are under investigation

The field awaits translation of the strong preclinical evidence for C1q as a therapeutic target into clinical benefit. Key questions remain about the optimal timing of intervention, patient selection, and safety of long-term complement inhibition.

Research Gaps And Future Directions

1. Temporal dynamics: When does C1q-mediated synapse loss become irreversible? What determines the transition from protective to pathological complement activation?

2. Cell-type specificity: What determines whether C1q acts protectively (debris clearance) vs. pathologically (synapse elimination)? Can we target pathological C1q while sparing beneficial functions?

3. Biomarkers: Development of validated C1q-related biomarkers for patient stratification and treatment monitoring

4. Combination therapies: How should C1q-targeted approaches be combined with other therapeutic strategies (anti-amyloid, anti-tau, neuroprotection)?

5. Species translation: How well do findings from mouse models translate to human disease? What role do species differences play?

See Also

• C1Q Protein (Complement Component 1q)

• C1QB — Complement Component 1Q Beta

• Complement System in Neurodegeneration

• Complement System Pathway in Neurodegeneration

• Microglia in Neurodegeneration

• Neuroinflammation and Microglia Pathway in Alzheimer’s Disease